SCHEMBL5289613

SCHEMBL5289613

CCCCOC(=O)c1cc2ccccc2[nH]1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 2/20 0.59
DRD3 P35462 1/20 0.59
KDM4E B2RXH2 9/20 0.58
ALDH1A1 P00352 7/20 0.58
HPGD P15428 5/20 0.58
LMNA P02545 4/20 0.58
RAB9A P51151 3/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
MAPT P10636 3/20 0.58
NPC1 O15118 2/20 0.58
GAA P10253 2/20 0.58
MEN1 O00255 1/20 0.58
GLA P06280 1/20 0.58
KMT2A Q03164 1/20 0.58
ATM Q13315 1/20 0.58
L3MBTL1 Q9Y468 3/20 0.57
TP53 P04637 1/20 0.57
TSHR P16473 4/20 0.55
TDP1 Q9NUW8 1/20 0.54
PDGFRB P09619 3/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6533183 0.96 DRD2 (0.58) DRD2DRD3KDM4EALDH1A1HPGD
SCHEMBL5935742 0.94 GPR84 (0.58) DRD2DRD3KDM4EALDH1A1HPGD
SCHEMBL7169528 0.91 KDM4E (0.61) DRD2DRD3KDM4EALDH1A1HPGD
SCHEMBL24960989 0.87 KDM4E (0.56) DRD2DRD3KDM4EALDH1A1HPGD
SCHEMBL22265093 0.87 KDM4E (0.58) DRD2DRD3KDM4EALDH1A1HPGD
SCHEMBL4519869 0.86 AKR1C3 (0.58) DRD2DRD3KDM4EALDH1A1HPGD
SCHEMBL29580772 0.85 KDM4E (0.78) DRD2DRD3KDM4EALDH1A1HPGD
SCHEMBL42002 0.85 KDM4E (0.78) DRD2DRD3KDM4EALDH1A1HPGD
SCHEMBL4529329 0.84 KDM4E (0.52) DRD2DRD3KDM4EALDH1A1HPGD
Hydrochloric Acid SCHEMBL16115604 0.84 KDM4E (0.76) DRD2DRD3KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116425751-B Polycyclic compounds as MAT2A inhibitors 艾立康药业股份有限公司 2024-01-23 CN disclosed
EP-1836192-A2 ARYL PIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS Universita' Degli Studi di Siena (IT) 2007-09-26 EP disclosed
US-20070010559-A1 Indole derivatives for use as chemical uncoupler NOVO NORDISK A/S (DK) 2007-01-11 US disclosed
EP-1689710-A1 INDOLE DERIVATIVES FOR USE AS CHEMICAL UNCOUPLER NOVO NORDISK A/S (DK) 2006-08-16 EP disclosed
WO-2006072608-A2 ARYL PIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS UNIVERSITÁ DEGLI STUDI DI SIENA (IT) 2006-07-13 WO disclosed
WO-2005051908-A1 INDOLE DERIVATIVES FOR USE AS CHEMICAL UNCOUPLER NOVO NORDISK A/S (DK) 2005-06-09 WO disclosed
EP-1165511-A2 METHOD OF PRODUCING HETEROCYCLIC CARBAMATES FROM AZA-HETEROCYCLIC COMPOUNDS AND CARBON DIOXIDE GÖDECKE GMBH (DE) 2002-01-02 EP disclosed
WO-2000058286-A2 METHOD OF PRODUCING HETEROCYCLIC CARBAMATES FROM AZA-HETEROCYCLIC COMPOUNDS AND CARBON DIOXIDE Gödecke GmbH (DE) 2000-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010559-A1 Indole derivatives for use as chemical uncoupler GPR119, IDO2, IDO1 DRD2 626/4885DRD3 418/4885KDM4E 434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.